I submitted a question during the last cc asking what were the options on the table for additional non funding, both dilutive and non dilutive..The question didn’t get presented. I think this question needs to be asked by multiple shareholders at the next cc so it gets some form of answer. I agree covid is the revenue generation needed now. Even if the U.K. funds some of the trial it will come up short. We need to shift gears a bit in our questioning from the drug to the financial stability of the company.